Are there any upcoming regulatory milestones or trial results mentioned that might move the price?
Short answer:
No. The announcement about Alnylamâs participation in the CanaccordâŻGenuity 45th Annual Growth Conference does not mention any upcoming regulatory milestones (e.g., FDA/EMA filings, advisory committee meetings) or the release of new trial data that could act as a catalyst for the stock price.
Why this matters
When a companyâs investorâevent press release highlights a forthcoming regulatory decision (e.g., a BLA submission, a PDUFA date, a European Medicines Agency (EMA) CHMP recommendation) or the publication of pivotal trial results, analysts and investors often anticipate a nearâterm price move. Those items are typically listed explicitly in the âUpcoming Eventsâ or âMilestonesâ sections of the release.
In this case, the only details provided are:
| Item | Description |
|---|---|
| Event | Management will give a companyâoverview presentation at the CanaccordâŻGenuity 45th Annual Growth Conference (Tuesday,âŻAugâŻ12âŻ2025,âŻ8:00âŻamâŻET). |
| Webcast | Live audio webcast on Alnylamâs investor page; replay available within 48âŻhours. |
| No mention of | ⢠Upcoming FDA/EMA submissions or meetings ⢠Anticipated advisory committee hearings ⢠Anticipated data readâouts (e.g., PhaseâŻ3 primary endpoint results, interim analyses, or data from ongoing trials such as AROâRNAi, ALNâ212, etc.) ⢠Expected regulatory timelines (e.g., PDUFA dates, EMA CHMP recommendations). |
Because none of those catalysts are disclosed, there is no explicit information in this release that would suggest a nearâterm regulatory or dataâdriven price catalyst.
What to watch for (outside this release)
Even though the press release itself is silent, investors often use conference calls to tease upcoming milestones. If Alnylamâs management hints at:
- Regulatory filings (e.g., a BLA for a new siRNA product, a supplemental NDA, or a European marketingâauthorisation application)
- Data readâouts from ongoing PhaseâŻ2/3 trials (e.g., for ALNâ101, ALNâ303, or any of the pipelineâs liverâ, cardiovascularâ, or CNSâtargeted programs)
then those would be considered potential priceâmoving events. As of the information provided, however, no such milestones are listed.
Bottom line
Based solely on the information in the news release:
- No upcoming regulatory milestones are mentioned.
- No trial results or data releases are referenced.
Therefore, from this specific announcement alone, there is no identified catalyst that would be expected to move Alnylamâs share price in the immediate future. Investors should monitor the actual conference presentation (or its replay) for any forwardâlooking statements that might introduce new milestones not captured in the press release.